Anti-hk2 chimeric antigen receptor (car)
AssigneeJanssen Biotech, Inc.
InventorsRaymond BRITTINGHAM, Rajkumar GANESAN, Sherry LA PORTE, John T. LEE, Jinquan LUO, Theresa MCDEVITT, Fei SHEN, Sanjaya SINGH, Degang SONG, Sathyadevi VENKATARAMANI, Fang YI, Yonghong ZHAO
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a human Kallikrein-2 (hK2), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
Claims42
A chimeric antigen receptor (CAR) comprising:
- (a) an extracellular domain that specifically binds to the human Kallikrein-2 (hK2) antigen,
- (b) a transmembrane domain, and
- (c) an intracellular signaling domain optionally comprising at least one co-stimulatory domain.
A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises:
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 64, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 66;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 314, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 315, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 311;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 309, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 310, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 311;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 63, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 65, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 66;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 72, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 73, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 66;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 86, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 87, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 88;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 92, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 93, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 94;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 102, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 103, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 104;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 105, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 106, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 104;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 107, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 108, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 109;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 110, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 111, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 109;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 102, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 112, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 113;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 105, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 114, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 113;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 115, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 116, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 117;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 118, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 119, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 117;
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 120, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 121, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 122;
- or
- a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 123, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 124, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 122,
- wherein the extracellular antigen-binding domain binds the hK2 antigen.
A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises:
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 67, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 69, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 71;
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 68, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 70, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 71;
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 89, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 90, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 91;
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 95, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 96, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 71;
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 312, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 313, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 91;
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 89, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 90, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 91;
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 67, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 126, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 71;
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 128, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 129, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 130;
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 125, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 131, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 132;
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 133, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 134, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 135;
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 136, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 137, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 138;
- or
- a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:
- 97, a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 127, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 139,
- wherein the extracellular antigen-binding domain binds the hK2 antigen.
A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular antigen-binding domain comprises:
- a light chain variable domain (VL) comprising an amino acid sequence selected from SEQ ID NOS:
- 1, 2, 3, 74, 75, 147, 148, 149, 150, 151, 152 and 318;
- and/or
- a heavy chain variable domain (VH) comprising an amino acid sequence selected from SEQ ID NOS:
- 4, 5, 6, 76, 77, 140, 141, 142, 143, 144, 145, 146 and 317;
- wherein the extracellular antigen-binding domain binds the human Kallikrein-2 (hK2) antigen.
Dependencies are inferred from the claim text.